Elekta (EKTAY) versus Its Competitors Financial Review

Elekta (OTCMKTS:EKTAY) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Elekta to similar companies based on the strength of its earnings, profitability, risk, institutional ownership, analyst recommendations, valuation and dividends.

Volatility and Risk

Elekta has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Elekta’s competitors have a beta of 2.56, suggesting that their average share price is 156% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Elekta and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elekta	0	1	0	0	2.00
Elekta Competitors	4262	10493	18230	825	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 23.00%. Given Elekta’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Elekta has less favorable growth aspects than its competitors.

Dividends

Elekta pays an annual dividend of $0.12 per share and has a dividend yield of 2.0%. Elekta pays out -100.0% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.2% and pay out 44.8% of their earnings in the form of a dividend.

Earnings and Valuation

This table compares Elekta and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Elekta	$1.78 billion	-$55.38 million	-50.00
Elekta Competitors	$1.87 billion	$138.21 million	10.91

Elekta’s competitors have higher revenue and earnings than Elekta. Elekta is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 41.3% of Elekta shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Elekta and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elekta	-2.38%	13.47%	3.84%
Elekta Competitors	-278.24%	-150.08%	-21.87%

Summary

Elekta competitors beat Elekta on 10 of the 15 factors compared.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.